FDA gives breakthrough therapy designation to experimental hepatitis C regimen

AbbVie tests interferon-free combination therapy

NORTH CHICAGO, Ill. — An experimental drug regimen under development by AbbVie could change the way hepatitis C is treated, according to a special designation it received from the Food and Drug Administration.

AbbVie said the FDA granted breakthrough therapy designation to its direct-acting antiviral, or DAA combination drug therapy consisting of three drugs, which go under the code names ABT-450/r, ABT-267 and ABT-333, with or without the common antiviral drug ribavirin. The agency uses breakthrough therapy designation to promote expedited development and review of drugs for serious or life-threatening conditions that have the potential to significantly improve treatment. The drug is part of a therapy regimen that would allow for elimination of interferons, biotech drugs for hepatitis C that, while effective, also carry harmful side effects.

The drug currently is in phase-3, or late-stage clinical development, and the FDA designation was granted on the basis of results from a phase-2b trial titled "Aviator," in 571 patients.

The drug maker said that after 12 weeks of treatment, a high rate of patients who had not received treatment for hepatitis C before or who had failed treatment with combination interferon and ribavirin therapies had shown high sustained viral response, or SVR rates, essentially meaning they were cured. This included 99% of those who had not received treatment and 93% of those who had failed interferon-ribavirin treatment, with only one relapse and four of the 247 patients treated for 12 and 24 weeks with triple DAA and ribavirin dropping out due to harmful side effects.


Login or Register to post a comment.